The CDSCO has released new guidelines to compound minor drug violations, operationalizing a legal change in progress since 2023.
The guidelines aim to standardize compounding, allowing firms to settle certain offenses by paying a fine instead of facing litigation, at the regulator's discretion.
This change is based on the Jan Vishwas (Amendment of Provisions) Act, which decriminalizes and rationalizes offenses to improve ease of living and doing business.
The Jan Vishwas Act broadened Section 32B of the Drugs and Cosmetics Act, 1940, to include offenses that can be compounded.
Detailed Insights:
The Jan Vishwas Act allows compounding for offenses like making drugs for sale or distribution in breach of the 1940 Act, but not covered by Section 27(a-c), and stocking or exhibiting such non-spurious or non-adulterated drugs.
Compounding, if granted and paid for, provides "immunity from prosecution" for the specific case, contingent upon certain conditions.
The guidelines could potentially turn into a 'pay and pass' scheme if the CDSCO lacks transparency in publishing compounding orders and case details.
The absence of a publicly auditable trail and the lack of opportunity for consumer groups or whistle-blowers to make representations could erode public trust.
The broad definition of compoundable errors may cover a wide range of behaviors, from paperwork lapses to more significant compliance failures.
The CDSCO needs to link compounding to corrective actions, follow-up inspections, and public-facing actions like alerts or product recalls to ensure a lasting reduction in risk.
Key Concepts Involved:
Compounding: A process where firms can settle certain offenses by reporting them and paying a fine, instead of facing litigation.
Decriminalization: The process of reducing or removing criminal penalties for certain actions or offenses.
Standard Operating Procedures: A set of step-by-step instructions compiled by an organization to help workers carry out complex routine operations.